Dashunin,V.M.; Maeva,R.V., Journal of Organic Chemistry USSR (English Translation), 1965, vol. 1, p. 1003 - 1006
摘要:
DOI:
作为产物:
描述:
4,5-二氢-3-苯基-2-呋喃酮 在
铑 作用下,
以
乙醇 为溶剂,
60.0 ℃
、55.15 MPa
条件下,
反应 18.0h,
以to afford 8.6 g (92%) of the title compound的产率得到3-Cyclohexyldihydro-2(3H)-furanon
参考文献:
名称:
Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
摘要:
本发明揭示了具有11 Beta-HSD type 1拮抗活性的新型化合物I的公式,以及制备这种化合物的方法。在另一实施例中,本发明揭示了包括化合物I的制药组合物,以及使用这些化合物和组合物治疗糖尿病、高血糖、肥胖症、高血压、高脂血症、代谢综合征和与11 Beta-HSD type 1活性相关的其他疾病的方法。X-17377。
An electrophilictrifluoromethylation of ketene silyl acetals (KSAs) by hypervalent iodine reagents 1 and 2 has been developed. The reaction proceeds under very mild conditions in the presence of a catalytic amount of trimethylsilyl bis(trifluoromethanesulfonyl)imide (up to 2.5 mol %) as a Lewis acid providing a direct access to a variety of secondary, tertiary, and quaternaryα-trifluoromethyl esters
Regioselective Hydroformylation of Allylic Alcohols
作者:Thomas E. Lightburn、Omar A. De Paolis、Ka H. Cheng、Kian L. Tan
DOI:10.1021/ol200782d
日期:2011.5.20
hydroformylation of allylicalcohols is reported toward the synthesis of β-hydroxy-acid and aldehyde products. The selectivity is achieved through the use of a ligand that reversibly binds to alcohols in situ, allowing for a directed hydroformylation to occur. The application to trisubstituted olefins was also demonstrated, which yields a single diastereomer product consistent with a stereospecific addition of CO
据报道,烯丙醇的高度区域选择性加氢甲酰化可用于合成 β-羟基酸和醛产物。选择性是通过使用一种配体来实现的,该配体在原位可逆地结合醇,允许发生定向加氢甲酰化。还证明了三取代烯烃的应用,这产生了与 CO 和氢的立体有择加成一致的单一非对映异构体产品。
INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
申请人:Li Renhua
公开号:US20090099182A1
公开(公告)日:2009-04-16
The present invention discloses novel compounds of Formula I:
having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.